dslogo
azlogo

DESTINY-Breast07: Patient Demographics (Results from Part 1/Module 2 [T-DXd + Pertuzumab] as of October 15, 2021 DCO) 

Patient Disposition

Patient Disposition11. André F, Hamilton EP, Loi S, et al. Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anticancer agents in patients with advanced/metastatic HER2+ (DESTINY-Breast07) and HER2-low (DESTINY-Breast08) breast cancer [poster, supplement, and abstract]. Poster presented at: American Society of Clinical Oncology (ASCO) 2022 Congress; June 3-5, 2022; Chicago, IL. J Clin Oncol. 2022;40(suppl 16). Abs 3025. 

  • Data reported below are as of October 15, 2021 for Part 1/Module 2
  • A total of 7 patients were assigned to Module 2 and received the initial dose level of T-DXd plus pertuzumab (T-DXd 5.4 mg/kg IV Q3W plus pertuzumab 420 mg IV Q3W [loading dose of 840 mg]).
  • Five patients (71.4%) were ongoing treatment, while 2 patients (28.6%) had discontinued both T-DXd and pertuzumab due to withdrawal by patient (n=1) and an AE of decreased ejection fraction (n=1).

Patient Demographics

Patient Demographics11. André F, Hamilton EP, Loi S, et al. Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anticancer agents in patients with advanced/metastatic HER2+ (DESTINY-Breast07) and HER2-low (DESTINY-Breast08) breast cancer [poster, supplement, and abstract]. Poster presented at: American Society of Clinical Oncology (ASCO) 2022 Congress; June 3-5, 2022; Chicago, IL. J Clin Oncol. 2022;40(suppl 16). Abs 3025. 

Patient Demographics and Disease Characteristics in Part 1/Module 2.11. André F, Hamilton EP, Loi S, et al. Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anticancer agents in patients with advanced/metastatic HER2+ (DESTINY-Breast07) and HER2-low (DESTINY-Breast08) breast cancer [poster, supplement, and abstract]. Poster presented at: American Society of Clinical Oncology (ASCO) 2022 Congress; June 3-5, 2022; Chicago, IL. J Clin Oncol. 2022;40(suppl 16). Abs 3025. 
Characteristics

Part 1/Module 2

T-DXd + pertuzumab

n=7

Age, mean (range), years54.3 (38-66)
Female, n (%)7 (100)

Race, n (%)

Asian

White

 

6 (85.7)

1 (14.3)

Primary tumor location at diagnosis, n (%)

Breast

 

7 (100)

HER2 status, n (%)

IHC 3+

IHC 2+/ISH +

Missing

 

5 (71.4)

1 (14.3)

1 (14.3)a

ECOG PS, n (%)

0

1

 

4 (57.1)

3 (42.9)

aThe HER2 status for this patient was missing at the time of the data cutoff and was later confirmed to be IHC 3+.

Abbreviations

AE = adverse event

;

ECOG = Eastern Cooperative Oncology Group 

;

DCO = data cut-off

;

HER2 = human epidermal growth factor receptor 2

;

IHC = immunohistochemistry

;

ISH = in-situ hybridization

;

IV = intravenous

;

T-DXd = trastuzumab deruxtecan

;

PS = performance status

;

Q3W = every 3 weeks

References

1. André F, Hamilton EP, Loi S, et al. Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anticancer agents in patients with advanced/metastatic HER2+ (DESTINY-Breast07) and HER2-low (DESTINY-Breast08) breast cancer [poster, supplement, and abstract]. Poster presented at: American Society of Clinical Oncology (ASCO) 2022 Congress; June 3-5, 2022; Chicago, IL. J Clin Oncol. 2022;40(suppl 16). Abs 3025. 

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

Document ID: 325e86bc-2a1f-401a-b8d6-fa304896a85b
Last updated: 14-February-2023

©2023 AstraZeneca. All rights reserved.